• Elekta (Boston) said it would introduce new product offerings at the annual American Society for Therapeutic Radiology and Oncology (ASTRO; Fairfax, Virginia) meeting in Boston. The new product offerings include the Elekta Infinity, a digital linear accelerator, now available in the U.S. According to the company, Elekta Infinity increases speed and precision in delivering Volumetric Modulated Arc Therapy (VMAT), offering patients shortened treatment times with "the highest degree of precision." Other product developments Elekta plans to highlight during ASTRO include its Mosaiq 2.0, a comprehensive oncology charting solution designed to track patients from the moment they enter the cancer center through long-term follow-up; Monaco VMAT planning, a next-generation Intensity Modulated Radiotherapy treatment planning system featuring biological modeling, constrained optimization, and Monte Carlo dose calculation algorithms; Atlas-Based Autosegmentation, a software application that produces an estimate of the anatomy boundary contours needed to create a radiation treatment plan; and the Extend program, a complete system for extending the use of Leksell Gamma Knife Perfexion enabling clinicians to treat indications previously untreatable with Gamma Knife surgery.

• Intact Medical (Natick, Massachusetts) said it has received FDA clearance for the Intact Excise XL – a larger version of the company's FDA-approved wands, used with the Intact Breast Lesion Excision System (BLES). As with the Intact BLES, the Intact Excise XL procedure involves the insertion of a slender wand through a small incision in the breast to remove an intact sample of suspicious tissue for histopathologic analysis. The procedure can be performed in an office-based or outpatient setting, with the actual capture of the breast lesion completed in less than 20 seconds. Intact makes minimally invasive systems for the diagnosis and removal of breast lesions.

• Micrus Endovascular (San Jose, California) reported the initiation of the worldwide launch of its Neuropath guide catheter line. The Neuropath guide catheter line is designed with a flexible and visible tip that allows for ready vascular access, while maintaining good stability. This design is intended to allow neurointerventionalists with better vessel access and greater vessel selection in treating patients with complex anatomies. "The Neuropath marks our entry into the guide catheter market and therefore represents a 100% incremental revenue opportunity for us," said CEO/Chairman John Kilcoyne, CEO/chairman. "The Neuropath is another example of Micrus' commitment to the development of products that deliver clinical advantages to our physicians while bolstering our non-embolic product portfolio." Micrus Endovascular makes implantable and disposable medical devices for treatment of cerebral vascular diseases.

• Nuance Communications (Burlington, Massachusetts) has introduced its Dragon Medical 10 medical speech recognition software. Dragon claims the new software recognizes dictation nearly twice as fast as its previous release and yields an accuracy improvement of more than 20% over the previous release. The company said Dragon Medical 10 is the only Dragon NaturallySpeaking edition that enables clinicians to dictate directly into an electronic medical record (EMR) system, and rapidly edit and sign medical reports, speeding data input, reducing clicking and typing and, in turn, accelerating EMR use. Dragon Medical can be integrated with any Windows- or Citrix-based EMR system, including, but not limited to, those from Allscripts, Epic, Misys, GE Healthcare, NextGen, Siemens, eClinicalWorks, Meditech, McKesson, Cerner and Eclipsys. Nuance makes speech and imaging solutions for business and consumers.

No Comments